EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Estimating copy number to determine BRCA2 deletion status and to expect prognosis in localized prostate cancer

Takuhisa Nukaya, Makoto Sumitomo iD, Eiji Sugihara, Mayu Takeda, Sachio Nohara, Shigeki Tanishima, Masashi Takenaka, Kenji Zennami, Kiyoshi Takahara, Ryoichi Shiroki, Hideyuki Saya

Cancer Medicine · 2023-04 · 12 (7) · 8154-8165

DOI: 10.1002/cam4.5617 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 16.01.2023. Verfasst von Takuhisa Nukaya und 10 weiteren Autor:innen. Beteiligte Einrichtung: Fujita Cancer Center, Fujita Health University, Toyoake, Japan. Hauptthemen laut MEDLINE: DNA Copy Number Variations, Prostatic Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The significance of BRCA alterations has been implicated in the development of metastatic castration‐resistant prostate cancer (PC). The details of the frequency and significance of BRCA alterations in localized PC remain unknown. In this study, we investigated the frequency and clinical significance of BRCA alterations in localized PCs using an in‐house next‐generation sequencer (NGS) system.

Methods

DNA was extracted from formalin‐fixed paraffin‐embedded tissues of surgical specimens from 126 patients with clinically localized PC who underwent radical prostatectomy. The mutation information of 164 cancer genes was analyzed using the PleSSision‐Rapid test. Both copy number (CN) variation and loss of heterozygosity of various genes, such as BRCA1 and BRCA2 , were estimated and reported.

Results

Next‐generation sequencer analyses revealed that the BRCA2 CN was decreased in 17 patients (13.5%) and the BRCA1 CN in six (4.8%) patients. NGS‐based CN values were shown to be highly correlated with droplet digital PCR‐based CN values. Tissue‐specific BRCA expression investigated using the Human Protein Atlas showed that the decreased CN of BRCA2 , but not BRCA1 , is responsible for the decreased BRCA activity in PC. Ten of the 22 patients with decreased BRCA2 CN were presumed to have somatic heterozygous deletion. There were no observed associations between the heterozygous deletion of BRCA2 and various clinicopathological parameters. Furthermore, three of 10 patients developed biochemical recurrence within 3 months after surgery. Multivariate analyses revealed that the initial prostate‐specific antigen levels and BRCA2 CN were independent factors for biochemical recurrence.

Conclusion

Our results suggest that a decrease in BRCA2 CN may be used as a biomarker for predicting recurrence after surgery in localized PC. Early screening for somatic alterations in BRCA2 using NGS may help to broadly predict the risk of PC progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA Copy Number VariationsProstatic NeoplasmsMaleHumansGenes, BRCA2MutationBRCA1 ProteinPrognosisGerm-Line MutationBRCA2 Protein

Stichwörter der Autor:innen

BRCA2copy numberloss of heterozygosityprognostic valueprostate cancer

Substanzen

BRCA1 ProteinBRCA2 protein, humanBRCA2 Protein

Autor:innen und Institutionen

  • Fujita Cancer Center, Fujita Health University, Toyoake, Japan.
  • Department of Urology School of Medicine, Fujita Health University, Toyoake, Japan.
  • Department of Medical Research for Intractable Disease, Fujita Health University, Toyoake, Japan.
  • Research Promotion Headquarters, Open Facility Center, Fujita Health University, Toyoake, Japan.
  • Department of Bio Informatics, Communication Engineering Center, Electronic System Business Group, Mitsubishi Electric Software Corp, Tokyo, Japan.

ORCID-Profile: Makoto Sumitomo

Zitieren

APA

Nukaya, T., Sumitomo, M., Sugihara, E., Takeda, M., Nohara, S., Tanishima, S., Takenaka, M., Zennami, K., Takahara, K., Shiroki, R., & Saya, H. (2023). Estimating copy number to determine BRCA2 deletion status and to expect prognosis in localized prostate cancer. Cancer Medicine, 12(7), 8154-8165. https://doi.org/10.1002/cam4.5617

Vancouver

Nukaya T, Sumitomo M, Sugihara E, Takeda M, Nohara S, Tanishima S, et al. Estimating copy number to determine BRCA2 deletion status and to expect prognosis in localized prostate cancer. Cancer Medicine. 2023;12(7):8154-8165. doi:10.1002/cam4.5617

BibTeX
@article{Nukaya2023,
  author = {Nukaya, Takuhisa and Sumitomo, Makoto and Sugihara, Eiji and Takeda, Mayu and Nohara, Sachio and Tanishima, Shigeki and Takenaka, Masashi and Zennami, Kenji and Takahara, Kiyoshi and Shiroki, Ryoichi and Saya, Hideyuki},
  title = {Estimating copy number to determine BRCA2 deletion status and to expect prognosis in localized prostate cancer},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {7},
  pages = {8154--8165},
  doi = {10.1002/cam4.5617}
}
Kostenlos starten →